Scilex Holding Company (SCLX) — Stock Valuation & Research

Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing…

SCLX key statistics

Price$1.99
Market cap$14M
SectorHealthcare
IndustryDrug Manufacturers - General
ExchangeNASDAQ
52-week range1.83-27
Beta1.79

Explore SCLX's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.